Nilotinib therapy after resistance to imatinib | Zendy

Raffaele Porrini | Zendy; Enrico Montefusco | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nilotinib therapy after resistance to imatinib

Author(s) -

Raffaele Porrini,

Enrico Montefusco

Publication year - 2015

Publication title -

clinical management issues

Language(s) - English

Resource type - Journals

eISSN - 2283-3137

pISSN - 1973-4832

DOI - 10.7175/cmi.v6i2s.1137

Subject(s) - nilotinib , medicine , imatinib , tyrosine kinase inhibitor , myeloid leukemia , tyrosine kinase , pharmacology , chronic myeloid leukaemia , oncology , receptor , cancer

In this article we present the case of a 43-year-old man with chronic myeloid leukemia (CML) successfully treated with nilotinib. At presentation we started him on imatinib at standard dose of 400 mg/day but after 36 months of treatment the patient didn’t achieve a molecular response. We switched him on second-generation tyrosine kinase inhibitor (TKI), nilotinib, at the dose of 800 mg/day. After twelve months on nilotinib the patient obtained a complete molecular response. During treatment with nilotinib we did not observe any drug-related toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research